arXiv:2404.01358

Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists

Alon Bartal, Kathleen M. Jagodnik, Nava Pliskin, Abraham Seidmann

제출 2024-04-01

원문 초록

Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA), a market expected to grow exponentially to $133.5 billion USD by 2030. Using a Named Entity Recognition (NER) model, our method successfully detected 21 potential ASEs overlooked upon FDA approval, including irritability and numbness. Our data-analytic approach revolutionizes the detection of unreported ASEs associated with newly deployed drugs, leveraging cutting-edge AI-driven social media analytics. It can increase the safety of new drugs in the marketplace by unlocking the power of social media to support regulators and manufacturers in the rapid discovery of hidden ASE risks.

함께 살펴볼 논문

공통 태그를 근거로 연결했습니다. 실제 인용 관계나 논문의 우수성을 뜻하지 않습니다.

arXiv:2504.16007공통 태그 Named Entity Recognition (NER), NER, named-entity-recognition, Named Entity Recognition공식 코드 · Papers with Code

Methods for Recognizing Nested Terms

토론

이 논문과 연결된 포럼 글이 아직 없습니다.